08:00 , Feb 14, 2011 |  BC Week In Review  |  Clinical News

BIO-11006 Inhalation Solution: Phase IIa data

The double-blind, U.S. Phase IIa BREATH 1 trial in 172 patients with moderately severe COPD showed that twice-daily 75 mg BIO-11006 missed the primary endpoint of significantly improving FEV1 from baseline to day 21 vs....
07:00 , Apr 27, 2009 |  BC Week In Review  |  Clinical News

BIO-11006 Inhalation Solution: Phase II ongoing

BioMarck said an independent safety monitoring committee recommended continuation of the double-blind, placebo-controlled, U.S. Phase II BREATH-1 trial based on a review of safety data from the first 75 mg dose group. The company will...
07:00 , Jul 7, 2008 |  BC Week In Review  |  Clinical News

BIO-11006 Inhalation Solution: Phase II started

BioMarck began the double-blind, placebo-controlled, U.S. Phase II BREATH-1 trial to evaluate 75, 150 or 250 mg of inhaled BIO-11006 given once daily for 3 weeks in 162 patients. BioMarck Pharmaceuticals Ltd. , Raleigh, N.C....
08:00 , Feb 11, 2008 |  BC Week In Review  |  Clinical News

BIO-11006 Inhalation Solution: Phase I data

In a double-blind, placebo-controlled Phase I trial (BIM-CL-002) in 59 volunteers, single and multiple doses of BIO-11006 were safe and well tolerated. The company plans to begin a Phase II trial in COPD patients with...
08:00 , Feb 11, 2008 |  BC Week In Review  |  Clinical News

BIO-11006 Inhalation Solution: Phase I data

In a double-blind, placebo-controlled Phase I trial (BIM-CL-001) in 8 volunteers, single doses of BIO-11006 were safe and well tolerated. The company plans to begin a Phase II trial in COPD patients with chronic bronchitis...
07:00 , Oct 22, 2007 |  BC Week In Review  |  Clinical News

BIO-11006 inhalation Solution: Phase II start

Next quarter, BioMarck will begin a Phase II trial. BioMarck Pharmaceuticals Ltd. , Raleigh, N.C.   Product: BIO-11006 inhalation Solution   Business: Pulmonary   Molecular target: NA   Description: Inhibitor of pulmonary inflammation and mucus...